<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; hybrid</title>
	<atom:link href="http://www.tapanray.in/tag/hybrid/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Growing Intricacies of Today’s Field Staff Role And The Path Ahead</title>
		<link>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=growing-intricacies-of-todays-field-staff-role-and-the-path-ahead</link>
		<comments>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/#comments</comments>
		<pubDate>Mon, 30 Jan 2023 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[field. staff]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[hybridization]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intricacies]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10742</guid>
		<description><![CDATA[With a varying degree, and in various forms, a hybrid working model is now gaining greater acceptance of several top pharma companies, across the world, just as in many other industries. This trend gets echoed in an article of December 07, 2022, &#8230; <a href="http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shape of Future Pharma Operations – Emerging A Pragmatic Outlook?</title>
		<link>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shape-of-future-pharma-operations-emerging-a-pragmatic-outlook</link>
		<comments>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/#comments</comments>
		<pubDate>Mon, 12 Apr 2021 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[in-person]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Pragmatic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10468</guid>
		<description><![CDATA[Just as newer reports come almost every day on safety, efficacy, dosage interval or span of immunity of Covid vaccines, similar reports are also reaching us about the possible future shape of pharma sales and marketing operations. Some hardcore optimists, &#8230; <a href="http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Still Evolving: Pharma’s New Pathway For Digital And F2F Customer Engagement</title>
		<link>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement</link>
		<comments>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/#comments</comments>
		<pubDate>Mon, 15 Feb 2021 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[areas]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Customer-Engagement]]></category>
		<category><![CDATA[Digital F2F]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Evolving. Pharma]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[inbound]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interactions]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outbound]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[preference]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[uncertain]]></category>
		<category><![CDATA[visits]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10415</guid>
		<description><![CDATA[Last year &#8211; probably left with no better choice &#8211; the pharma industry, in general, had to take an unprecedented interest in digitalization of business processes. It happened faster than ever, especially in the marketing domain, along with a few &#8230; <a href="http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Adopt A Hybrid Business Model For Better Sales &#8211; Not A Large Field Force</title>
		<link>http://www.tapanray.in/adopt-a-hybrid-business-model-for-better-sales-not-a-large-field-force/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=adopt-a-hybrid-business-model-for-better-sales-not-a-large-field-force</link>
		<comments>http://www.tapanray.in/adopt-a-hybrid-business-model-for-better-sales-not-a-large-field-force/#comments</comments>
		<pubDate>Mon, 29 Apr 2019 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Augmented]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[enhancing]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[field]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[higher]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[MRdownsizing]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[orders]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[ratio]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[satisfaction]]></category>
		<category><![CDATA[SFE]]></category>
		<category><![CDATA[Synergy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vision]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9511</guid>
		<description><![CDATA[For aggressive business expansion or to attain greater market access, creating a large sales force has been the thumb rule in the pharma industry, since long. To meet the challenge of changing market dynamics, going for a thorough re-engineering of &#8230; <a href="http://www.tapanray.in/adopt-a-hybrid-business-model-for-better-sales-not-a-large-field-force/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/adopt-a-hybrid-business-model-for-better-sales-not-a-large-field-force/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
